Mednet Logo
HomeHematology
Hematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

In your practice, what premedications do you use for subcutaneous daratumumab?

2 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Chicago

We administer the following pre-infusion medications 1 hour to 3 hours before the first 4 SQ infusions, and then we drop all premedications (except for dexamethasone) thereafter: Dexamethasone 20-40 mg Acetaminophen 650 mg Diphenhydramine 25 mg Montelukast 10 mg [this is not in the package insert b...

Do you continue daratumumab beyond 24 months in first line treatment of amyloidosis?

3 Answers

Mednet Member
Mednet Member
Medical Oncology · Mayo Clinic Rochester

This is an important and common clinical question, and one for which prospective data are currently limited. For background, the ANDROMEDA clinical trial (Kastritis et al., PMID 34192431) demonstrated that the addition of daratumumab to cyclophosphamide, bortezomib, and dexamethasone (CyBorD) signif...

What is your approach to iron deficiency anemia after a negative EGD and colonoscopy?

2
3 Answers

Mednet Member
Mednet Member
Gastroenterology · Icahn School of Medicine at Mount Sinai

If there is no sign of atrophic gastritis and repeated fecal tests for blood are negative, I’d look first for celiac disease. If all the celiac screening tests rule it out, then I might team up with a hematologist to look for rare birds like transferrin deficiency. I’d probably ease back on PPIs if ...

Would you consider upfront, time-limited anti-IL-5 therapy for I-HES or L-HES to avoid steroid side effects?

1 Answers

Mednet Member
Mednet Member
Hematology · Dalhousie University, Canada

There are two parts to this question: Are there better options than steroids for the treatment of iHES and L-HES? The answer is an emphatic yes. These are chronic diseases, and steroids are really not the optimal therapy. IL-5 inhibitors such as mepolizumab and benralizumab are effective in reducing...

What is your preferred first line treatment regimen for patients with untreated transplant-ineligible MM?

10
9 Answers

Mednet Member
Mednet Member
Medical Oncology · Massachusetts General Hospital

For transplant-ineligible patients, there are many excellent choices, including RVD lite and Dara Rd. My practice has shifted to Dara Rd for several reasons: The HR for Dara Rd v. Rd which is 0.56 appears to be better than the HR for RVd v. Rd in SWOG 0777, where it was 0.712 (though it should be no...

How do you work up patients with low level monoclonal lymphocytosis and adenopathy?

1
5 Answers

Mednet Member
Mednet Member
Medical Oncology · Ohio State University

In the setting where the blood has a CLL-like clone but does not meet criteria for CLL, I would obtain a lymph node biopsy to confirm the diagnosis of SLL. Although this is most likely to be the case, MBL clones can be seen in the blood concomitantly with other cancers as well.

If a pregnant patient with a mechanical heart valve takes warfarin throughout her pregnancy, what are the chances that the fetus will be harmed?

1 Answers

Mednet Member
Mednet Member
Cardiology · University of Southern California

Warfarin is effective for thromboembolic prevention in pregnant patients with mechanical valves. There is however an overwhelming evidence that warfarin taken during pregnancy is deleterious to the fetus. Its use during the first 6–12 weeks of gestation can be associated with important fetal complic...

Would you recommend ISRT for an initially bulky nodular lymphocyte predominant Hodgkin lymphoma with complete metabolic response after 4 cycles of R-CHOP?

3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Duke University Medical Center

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma. Approximately 95% of Hodgkin lymphoma cases are classified as classic Hodgkin lymphoma, including the nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted subtypes, all of which a...

Are there still clinical situations in which you deliberately treat patients with a DOAC besides apixaban?

2
6 Answers

Mednet Member
Mednet Member
General Internal Medicine · University of Chicago

Thank you for your question. Apixaban has been my preferred agent for a long time for patients requiring therapeutic anticoagulation. Apixaban’s lower bleeding risk was shown prior to and now has additional evidence to support this with the COBRRA trial. The risk is also ameliorated by the safety in...

Do you recommend a workup for POEMS and/or amyloidosis for IgM monoclonal gammopathies associated with neuropathy?

1
3 Answers

Mednet Member
Mednet Member
Medical Oncology · Brigham and Women's Hospital

While IgM monoclonal disorders, amyloidosis, and POEMS syndrome may all be associated with peripheral neuropathy, they are not often confused with one another. A patient with a peripheral neuropathy can be diagnosed most simply by a serum protein electrophoresis. The presence of a monoclonal IgM spi...